Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07345494 · ClinicalTrials.gov registry record
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
A clinical trial of Hypoparathyroidism, sponsored by Ascendis Pharma A/S.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT07345494 is a study of Hypoparathyroidism that is actively recruiting participants, run by Ascendis Pharma A/S. The registered enrollment target is 50 participants, below the 195-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07345494, a study of Hypoparathyroidism, is actively recruiting participants, sponsored by Ascendis Pharma A/S.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
Conditions Studied
Interventions
- DRUG Palopegteriparatide
Study Locations (1)
West Virginia
- Ascendis Investigational Site - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2036-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07345494
The ClinicalTrials.gov registry entry for NCT07345494 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (74% lower). The listed sponsor is Ascendis Pharma A/S, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypoparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which Palopegteriparatide is the first listed.
NCT07345494 reports 1 study location spanning 1 distinct geographic area - top geographies include West Virginia.
Frequently Asked Questions
What is clinical trial NCT07345494 about?
NCT07345494 is a clinical study titled "A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding". The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes thr...
What is the current status of trial NCT07345494?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2026-02-18. Estimated completion is 2036-01.
What conditions does trial NCT07345494 study?
This clinical trial studies the following conditions: Hypoparathyroidism.
What interventions are being tested in trial NCT07345494?
The interventions under investigation include: Palopegteriparatide (DRUG).
Who is sponsoring clinical trial NCT07345494?
This trial is sponsored by Ascendis Pharma A/S, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07345494 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hypoparathyroidism Natural History Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
RECRUITING · Phase 1
-
A Registry for Participants With Chronic Hypoparathyroidism
ACTIVE NOT RECRUITING
-
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
ACTIVE NOT RECRUITING · Phase 2
-
Use of NPSP558 in the Treatment of Hypoparathyroidism
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.